Machine-learning techniques, statistical imputation, and natural language processing give more accurate forecasts of clinical trial outcomes, durations, probabilities of approval, and financial performance
By managing risk through systematic portfolio construction methods, all biopharma stakeholders can lower the cost of capital and improve risk-adjusted returns, bringing more capital into this important sector
Better financing structures and business decisions will help bring more therapies to patients faster and, ultimately, cheaper
News
Ask a Question
Want to know more? Send us a message!